Altimmune to Provide Corporate Update at the Ladenburg Thalmann 3rd Annual Healthcare Conference

GAITHERSBURG, Md., Sept. 19, 2017 -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate overview at the Ladenburg Thalmann 3^rd Annual Healthcare Conference, taking place Tuesday, September 26 at the Sofitel Hotel in New York City.

Presentation Details
Date:        Tuesday, September 26
Time:        12:00pm Eastern Time
Location:   Sofitel Hotel New York City, St. Germain Ballroom
Webcast:   http://wsw.com/webcast/ladenburg3/alt

About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.

Altimmune Contacts
Bill Enright
President and CEO
Phone: 240-654-1450
Email: [email protected]

Ashley Robinson
Investor Relations
Phone: 617-775-5956
Email: [email protected]